Merck & Co’s Stock: Analyst Estimates & Ratings

Merck & Co., Inc. (MRK) is one of the world's leading pharmaceutical giants, known for developing breakthrough medicines and vaccines that have transformed healthcare globally. Headquartered in Rahway, New Jersey, the company has built a strong presence across oncology, vaccines, infectious diseases, and animal health, with blockbuster products like Keytruda driving its growth. Backed by decades of scientific innovation and a robust research pipeline, Merck continues to play a pivotal role in advancing treatments for some of the world's most challenging diseases.

With a market capitalization of roughly $316.95 billion, Merck has been a standout performer on Wall Street. The pharmaceutical giant's stock has surged 58.8% over the past year and gained 22% year-to-date (YTD) in 2026, comfortably outperforming the S&P 500 Index ($SPX), which has returned 22.6% over the past year and 13% in 2026.